H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 71 Citations 21,098 341 World Ranking 15061 National Ranking 557

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

His scientific interests lie mostly in Internal medicine, Immunology, Oncology, Surgery and Dendritic cell. His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology. His research integrates issues of Cytotoxic T cell and Chemotaxis in his study of Immunology.

His Oncology research is multidisciplinary, incorporating perspectives in Prostate cancer and Hazard ratio. His Surgery study integrates concerns from other disciplines, such as Placebo and Pazopanib. His Dendritic cell research is multidisciplinary, incorporating elements of Interleukin 3, Antigen-presenting cell and Chemokine.

His most cited work include:

  • Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial (1870 citations)
  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (1679 citations)
  • Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. (409 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Oncology, Prostate cancer, Immunology and Renal cell carcinoma are his primary areas of study. His Internal medicine research integrates issues from Gastroenterology and Surgery. His research in Oncology intersects with topics in Castration resistant, Enzalutamide and Phases of clinical research.

His study in Prostate cancer is interdisciplinary in nature, drawing from both Prostate and Docetaxel. He has included themes like Cytotoxic T cell and Melanoma in his Immunology study. His Renal cell carcinoma research includes elements of Carcinoma and Nephrectomy.

He most often published in these fields:

  • Internal medicine (43.21%)
  • Oncology (28.95%)
  • Prostate cancer (24.50%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (43.21%)
  • Prostate cancer (24.50%)
  • Oncology (28.95%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Internal medicine, Prostate cancer, Oncology, Clinical trial and Renal cell carcinoma. His is doing research in Clinical endpoint, Chemotherapy, Hazard ratio, Progression-free survival and Carboplatin, both of which are found in Internal medicine. He regularly links together related areas like Docetaxel in his Prostate cancer studies.

Ian D. Davis works in the field of Oncology, namely Adjuvant. His Clinical trial study combines topics from a wide range of disciplines, such as Quality of life and Family medicine. Ian D. Davis studied Renal cell carcinoma and Nivolumab that intersect with Ipilimumab.

Between 2018 and 2021, his most popular works were:

  • Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer (283 citations)
  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. (102 citations)
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented] (88 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Ian D. Davis mainly focuses on Prostate cancer, Internal medicine, Oncology, Clinical endpoint and Cabazitaxel. His studies in Prostate cancer integrate themes in fields like PET-CT, Nuclear medicine, Docetaxel and Consensus conference. Ian D. Davis undertakes interdisciplinary study in the fields of Internal medicine and Context through his research.

Ian D. Davis focuses mostly in the field of Oncology, narrowing it down to topics relating to MEDLINE and, in certain cases, Surgical excision. His Progression-free survival research incorporates elements of Darolutamide and Apalutamide. His Chemotherapy research is multidisciplinary, relying on both Gastroenterology and Placebo.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg;Ian D. Davis;Jozef Mardiak;Cezary Szczylik.
Journal of Clinical Oncology (2010)

2635 Citations

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot.
The New England Journal of Medicine (2014)

2407 Citations

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

Ian D. Davis;Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente.
Proceedings of the National Academy of Sciences of the United States of America (2004)

506 Citations

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

Cora N. Sternberg;Robert E. Hawkins;John Wagstaff;Pamela Salman.
European Journal of Cancer (2013)

416 Citations

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran.
European Urology (2018)

386 Citations

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis;Andrew J. Martin;Martin R. Stockler;Martin R. Stockler;Stephen Begbie.
The New England Journal of Medicine (2019)

366 Citations

Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma

M.E. Gleave;M. Elhilali;Y. Fradet;I. Davis.
The New England Journal of Medicine (1998)

341 Citations

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

Thomas E. Hutson;Ian D. Davis;Jean-Pascal H. Machiels;Paul L. De Souza.
Journal of Clinical Oncology (2010)

323 Citations

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

S Gillessen;A Omlin;G Attard;J S de Bono.
Annals of Oncology (2015)

300 Citations

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg.
Lancet Oncology (2014)

264 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ian D. Davis

Bernard Escudier

Bernard Escudier

Institut Gustave Roussy

Publications: 92

Cora N. Sternberg

Cora N. Sternberg

Cornell University

Publications: 89

Brian I. Rini

Brian I. Rini

Vanderbilt University Medical Center

Publications: 88

Toni K. Choueiri

Toni K. Choueiri

Harvard University

Publications: 83

Lloyd J. Old

Lloyd J. Old

Ludwig Cancer Research

Publications: 81

Andrew M. Scott

Andrew M. Scott

La Trobe University

Publications: 79

Robert J. Motzer

Robert J. Motzer

Memorial Sloan Kettering Cancer Center

Publications: 77

Karim Fizazi

Karim Fizazi

Institut Gustave Roussy

Publications: 75

Fred Saad

Fred Saad

University of Montreal

Publications: 70

Jonathan Cebon

Jonathan Cebon

La Trobe University

Publications: 69

Declan G. Murphy

Declan G. Murphy

Peter MacCallum Cancer Centre

Publications: 65

Johann S. de Bono

Johann S. de Bono

Institute of Cancer Research

Publications: 57

Thomas E. Hutson

Thomas E. Hutson

Texas Oncology

Publications: 56

Kim N. Chi

Kim N. Chi

BC Cancer Agency

Publications: 55

Sacha Gnjatic

Sacha Gnjatic

Icahn School of Medicine at Mount Sinai

Publications: 51

Joaquim Bellmunt

Joaquim Bellmunt

Beth Israel Deaconess Medical Center

Publications: 51

Something went wrong. Please try again later.